Innovative Journal Innovative Journal http://jmbas.in/index.php/jmbas Journal of Medical Biomedical and Applied Sciences 2589-8779 https://doi.org/10.15520/jcmro.v3i03.264 Safety and Efficacy of Imiquimod in the Treatment of Infantile Hemangioma; a Systematic Review and Meta-Analysis Effect of Imiquimod in Infantile Hemangioma Alakeel Abdullah 1 College of medicine, University medical city, King Saud University, Riyadh, Saudi Arabia 03 03 2020 Abstract:

Objective: To study the safety and efficacy of imiquimod in the treatment of infantile hemangioma (IH).

Method: Systematic search was conducted in nine electronic databases for selecting relevant articles reporting the safety and efficacy of imiquimod as a therapeutic agent for treatment of IH. Meta-analysis was used to pool the results.

Results: Of total 180 records screened, we included 9 studies for this systematic review and meta-analysis. About one-fifth of the patients (20.9%) have showed clinical resolution with 95% confidence interval (CI) of 11.8% to 34.1%. Regarding IH type, superficial type showed the highest rates of both clinical resolution and excellent response rates with 31.2% (95% CI= 16.6% to 50.8%) and 26.5% (95% CI= 11.6% to 49.6%), respectively. A relatively high prevalence of any side effects with 63.1% (95% CI= 47.6% to 76.3%) has been reported. The highest reported side effect was crustation (44.1%; 95% CI= 27.8% to 61.8%).

Conclusion: Imiquimod is effective in the treatment of superficial IH and it is associated with local side effects.

Keywords Imiquimod Infantile Hemangioma Systematic Review Introduction:

The two major types of vascular lesions in infants are; tumors and vascular malformations 1. The most common tumors in infancy, of a vascular origin, are hemangiomas. The exact incidence may not be known; however, the reported incidence is ranging from 4% to 10% of the Caucasian infants5, 4, 3, 2 Most of the hemangiomas are occurring in a sporadic way and in some cases, the autosomal dominant pattern of familial transmission; has been also reported 6. In a large series of 136 families having established infantile hemangiomas (IHs), about one-third of the patients have an associated family history; mostly among first-degree relatives 7. Noteworthy, IHs are three times more common among females (as compared to males) 10, 9, 8 and in non-Hispanic white races (as compared to other ethnic groups) 11, 10, 4. The most commonly reported risk factor is the low birth weight; hence, the preterm infants have an increased incidence of hemangiomas 10

The growth of IHs has a characteristic life cycle of two dynamic phases; proliferation and involution 14, 13, 12. A proliferation phase started at the early infancy, followed by an intermediate “plateau” phase during the mid-to-late infancy then the involution phase by the first year of life 14, 13, 12. Morphologically, IHs can be classified into three types; superficial, deep and mixed 15, 12 . The most common presentation is the superficial type which consists of a bright red lesion (a nodule, papule or plaque) raised above the skin; which is so-called a "strawberry" or "capillary" hemangioma 17, 16. The deep/subcutaneous type is a less common presentation with a typically raised colored skin nodule (a bluish hue) with/without a telangiectatic patch; which is so-called a "cavernous" hemangioma 16 . The mixed/combined IHs are the least common with having the features of both superficial and deep hemangiomas 16. It should be noted that most of the IHs are not clinically evident at birth and takes up to months to be noted 18, 9 .

Despite the fact that IHs are benign and self-limited in nature, they can cause serious complications such as ulceration or a permanent skin disfigurement 19, 12, 9. Furthermore, they may compromise the functions of a vital organ or develop life-threatening visceral hemangiomas 19, 12, 9. The approach to the treatment of hemangiomas should be individualized, based upon the size of the lesion, morphology, location, presence or possibility of complications, the potential for scarring or disfigurement, the age of the patient, and the rate of growth or involution at the time of evaluation 20, 16. The topical treatment is used mainly for uncomplicated IHs which includes topical beta-blockers, corticosteroids, and imiquimod 24, 23, 22, 21. Imiquimod is a topical immune response modifier with antiangiogenic and proapoptotic properties 24. The current evidence about the efficacy of imiquimod for the treatment IHs is conflicting 30, 29, 28, 27, 26, 25. In this study, we aim to summarize the available evidence in this regard with stressing on the possible side effects as well.

<bold id="s-aab0427cc8be">Method:</bold>

Search strategy and study selection:

The study process was conducted following the accepted methodology recommendations of the PRISMA checklist for systematic review and meta-analysis where registration of the protocol is not mandated 31. We conducted a systematic electronic database search for suitable studies from inception till 10th December 2019 in nine databases including Google Scholar, System for Information on Grey Literature in Europe (SIGLE), Scopus, Web of Science (ISI), PubMed, Virtual Health Library (VHL), Clinical trials.gov, metaRegister of Controlled Trials (mRCT) and The WHO International Clinical Trials Registry Platform (ICTRP) databases using the following search term: (imiquimod and infantile hemangioma). We conducted manual search of references in our included papers for collecting missed relevant studies 32. We included all relevant original publications reporting saftety and efficacy of treatment of infantile hemangioma with imiquimod. There were no restrictions on study design, country, language or publication date. Papers were excluded if there were one of the following exclusion criteria: i) in vitro or animal studies; ii) data duplication, overlapping or unreliably extracted or incomplete data; iii) abstract only articles, reviews, thesis, books, conference papers or articles without available full texts (conferences, editorials, author response, letters, and comments. Three independent reviewers screened title and abstract for selecting eligible papers. Further full text screening was performed to ensure the inclusion of relevant papers in our systematic review. Any disagreement was done by discussion and consulting the senior member when necessary.

Data extraction :

The data extraction form was developed by two authors, using a Microsoft Excel file. Three reviewers independently extracted data from included studies using the excel sheet. Data checking was performed through a fourth reviewer. All the disagreements and discrepancies were resolved by discussion and consultation with a senior member when necessary.

Quality assessment :

Three independent reviewers evaluated the risk of bias in included studies. The National Institutes of Health (NIH) quality assessment tool was used to assess the quality of each included studies 33. Quality assessment of each study was obtained through a scoring system including 14 questions. The criterion was judged as following; a score of 13 to 14 was good, 9 to 12 was fair, and studies scoring below 9 are considered of poor quality for cohort studies 34. Any discrepancy between the reviewers was solved by discussion.

Statistical analysis:

All data were analyzed using R software version 3.6.1 35. Using the “meta” package, different clinical response rates and the prevalence of side effects; have been calculated 36. The corresponding 95% confidence intervals (CI) of pooled effect size were calculated using a random-effects due to the presence of heterogeneity. Heterogeneity was assessed with Q statistics and I2 test considering it significant with I2 value > 50% or P-value < 0.0537. Publication bias could not be assessed using Egger’s regression test due to the small number of included studies (less than 10) 39, 38 .

Results:

Study characteristics:

Our systematic search yielded 232 reports. By using endnote software, we excluded 52 duplicates. Title and abstract screening resulted in exclusion of 153 reports inclusion of 27 reports for further full text screening. Seven articles were eligible for inclusion after full text screening. Additional two papers were added after performing manual search. Finally, we included 9 studies for this systematic review 48, 47, 46, 45, 44, 43, 42, 41, 40 Figure 1

Flow chart of theprocess of the review

Studycharacteristic table
Reference ID Study design Sample size Age in months (mean (SD)) Male (event) Type of IH (Event) QA
Superficial Mixed Deep
Ho/2007/Canada RC 18 18 *# 2 12 3 3 Fair
Jiang/2011/China PC 44 3.4 NR 31 13 - Fair
Mao/2012/China RC 19 NR 5 12 7 - Fair
McCuaig/2009/Canada PC 16 4.1 (1.9) 5 10 5 1 Fair
Qiu/2013/China RC 9 3.3 (1.7) 5 9 - - Fair
Seirafi/2012/Iran PC 15 9.1 (6.3) 5 NR NR NR Fair
Welsh/2004/USA PC 10 3-7 ** 4 10 - - Fair
Guo/2009/China PC 68 14 * 18 36 12 10 Fair
Hu / 2014 /China *** Non-RCT 54 14.6*# 26 54 - -
# = median, *= weeks, **= range, NR = not reported, RC = retrospective cohort, PC = prospective cohort, QA = quality assessment, *** non-meta-analyzed study.

There were three retrospective cohorts and five prospective ones and one non-randomized clinical trial Table 1. The sample size was 253 patients ranged from 9 to 68 patients. Regarding IH type, 164 patients had superficial IH, 40 had mixed IH, 14 had deep IH and the type was not reported in 25 patients. All studies were of fair criterion.

Clinical response rates

Five studies with 158 patients were assessed for clinical resolution rates, following the use of imiquimod. In the same context, five studies (155 patients), seven studies (180 patients), six studies (171 patients), and five studies (146 patients) have assessed different response degrees of excellent (100 to 75%), moderate (50 to 75%), minimal (25 to 50%), and poor response and /or failure (0 to 25%), respectively.

About one-fifth of the patients (20.9%) have showed clinical resolution with 95% CI of 11.8% to 34.1% Figure 2. Moreover, the reported rates of excellent and moderate responses were 18.3% (95% CI= 12.8% to 25.4%) and 20.2% (95% CI= 12.6% to 30.8%), respectively. Nevertheless, the reported minimal and poor/failure rate were considerably high with 29.2% (95% CI= 15.9% to 47.4%) and 34.3% (95% CI= 26.9% to 42.5%), respectively Figure 2.

Showingclinical response of infantile hemangioma after treatment of imiquimod

On the comparison of different types of hemangioma, superficial type showed the highest rates of both clinical resolution and excellent response rates with 31.2% (95% CI= 16.6% to 50.8%) and 26.5% (95% CI= 11.6% to 49.6%), respectively. In contrast, the worst response rates were reported in patients with deep hemangiomas where 66.7% (95% CI= 15.4% to 95.7%) of the cases showing poor response or treatment failure Figure 3.

Showingsubgroup analysis of infantile hemangioma after treatment of imiquimod

Prevalence of side effects

Three studies with 86 patients has reported the rates of different side effects. A relatively high prevalence of any side effects with 63.1% (95% CI= 47.6% to 76.3%) has been reported. The highest reported side effects were crustation (44.1%; 95% CI= 27.8% to 61.8%), erythema/edema (34.5%; 95% CI= 17.5% to 56.6%), and erosion/light crustation (31.6%; 95% CI= 14.9% to 54.8%). In contrast, the lowest reported side effects were nausea (5.3%; 95% CI= 0.7% to 29.4%), inflammation (5.6%; 95% CI= 0.8% to 30.7%), and peeling (6.8%; 95% CI= 2.2% to 19.1%), respectively Figure 4.

Showing theprevalence of side effects after treatment of infantile hemangioma with imiquimod

<bold id="s-930b05126fe3">Discussion:</bold>

IH is a common benign tumor in infancy affecting approximately 4 - 10%49. Mainly, IH requires no treatment as the major growth of IH occurs at 5 months with subsequent remission with the infant growth 50. However, if IH comprises a variable complications such as ulceration, interference with vision, airway and hearing; treatment is mandated 51. Moreover, cosmetic appearance of affected cases constitutes an important indication for treatment due to the interference of the psychological life of the child compared to healthy peers 52.

Different therapeutic modalities have been developed for the treatment of IH. Historically, the treatment of IH consists of corticosteroids, surgical excision and laser therapy 55, 54, 53. Due to the associated side effects of long term treatment with corticosteroids in addition to the contraindication of surgery in some children; emergence of new drugs has become the primary concern among physicians 56. Imiquimod is an immune-modulator drug that promotes the release of cytokines and tumor necrosis factor (TNF) directly and IFN gamma (IFN-У) which in part decrease the blood supply of IH in addition to limitation of their proliferation 58, 57.

In our study, the clinical resolution of IH treated with imiquimod was successful in one fifth of patients. In parallel with Ho et al 10 , study that reported a successful clinical resolution rate in 22% of the population. Additionally, Guo et al 47, indicated that a quarter of patients experienced clinical resolution of IH. On the contrary, clinical resolution was demonstrated as 7 and 16% for Jiang et al 41 , and Mao et al 42, respectively.

Subgroup analysis based upon IH type, showed that imiquimod is beneficial in promoting clinical resolution in nearly one third of superficial hemangioma patients in addition to providing a remarkable excellent and moderate improvement in approximately 25% and 20% of superficial IH patients, respectively. However, the drug had a minimal improvement and /or failure rates in nearly two thirds of deep type and half of mixed type of IH patients. The high efficacy in treating superficial but not deep and mixed type of IH can be explained through the topical action of the drug which may fail dramatically in reaching large parts of the deep and the mixed types of IH 41.

Despite being an efficient drug for treating superficial IH, various side effects had been reported through different studies ranging from local to systemic negative consequences 46, 42. In our study, the prevalence of patients -receiving imiquimod- that experienced side effects was 63%. Our results was nearly similar to Guo et al 47, where 59% of patients revealed one or more local side effects. However, 14 out of 16 patients in McCuaig et al 43, reported local skin reactions.

The side effects were mainly local in origin; however, two patients experienced fever, 1 reported nausea and vomiting affected one participant, Mao et al 42. Various local side effects were demonstrated by many studies such as ulceration, crustation, erythema, itching and sacring47, 46, 44, 41. The most common presented side effects in our study were crustation and erythema and edema revealing percentages of 44% and 34%, respectively. Similar observation was indicated by Jiang et al41 in which 55% of IH patients developed crustation, out of these two thirds were of superficial type and the other third was of mixed type. Furthermore, erythema and oedema was the most common negative conseqences associated with treatment of imiquimod with a percentage of 30% 47.

Limitations:

Our study should be interpreted with several limitations. Firstly, inclusion of retrospective cohort studies therefore selection bias could not be avoided. Secondly, the difference in age, sex and duration of the drug application may influence the reported efficacy and side effects as well; therefore, more studies are needed to address this issue.

Conclusion:

Imiquimod is effective in the treatment of superficial but not deep and mixed types of IH with moderate range of local side effects.

Funding: None

Declaration of Conflicting Interests: None

References Chang L. C. Haggstrom A. N. Drolet B. A. Baselga E. Chamlin S. L. Garzon M. C. Horii K. A. Lucky A. W. Mancini A. J. Metry D. W. Nopper A. J. Frieden I. J. Growth Characteristics of Infantile Hemangiomas: Implications for Management PEDIATRICS 2008 122 2 360 367 0031-4005, 1098-4275 10.1542/peds.2007-2767 American Academy of Pediatrics (AAP) https://dx.doi.org/10.1542/peds.2007-2767 Darrow D H Greene A K Mancini A J Nopper A J S O O.-H Section On Dermatology, S. Neck, et al. Diagnosis and Management of Infantile Hemangioma Pediatrics 2015 136 4 1060 104 Senchak A J Dann M Cable B Bessinger G Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases Ear Nose Throat J 2010 89 3 20229466 20229466 Van Den Abbeele Thierry Triglia Jean-Michel Lescanne Emmanuel Roger Gilles Nicollas Richard Ployet Marie-Josèphe Garabédian Eréa-Noël Narcy Philippe Surgical Removal of Subglottic Hemangiomas in Children The Laryngoscope 1999 109 8 1281 1286 0023-852X, 1531-4995 10.1097/00005537-199908000-00018 Wiley https://dx.doi.org/10.1097/00005537-199908000-00018 Welsh Oliverio Olazarán Zulema Gómez Minerva Salas Julio Berman Brian Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream Journal of the American Academy of Dermatology 2004 51 4 639 642 0190-9622 10.1016/j.jaad.2004.04.022 Elsevier BV https://dx.doi.org/10.1016/j.jaad.2004.04.022 Frieden I J Eichenfield L F Esterly N B Geronemus R Mallory S B Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee J Am Acad Dermatol 1997 37 4 9344205 9344205 Sidbury Robert Neuschler Nicole Neuschler Erin Sun Ping Wang Xiao-qi Puscasiu Elena Gugneja Sajiv Miller Richard Tomai Mark Paller Amy S. Topically Applied Imiquimod Inhibits Vascular Tumor Growth In Vivo Journal of Investigative Dermatology 2003 121 5 1205 1209 0022-202X 10.1046/j.1523-1747.2003.12521.x Elsevier BV https://dx.doi.org/10.1046/j.1523-1747.2003.12521.x Hu L Huang H Z Li X Lin X X Li W Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma Dermatology 2015 230 2 150 155 Mills C M Marks R Side effects of topical glucocorticoids Curr Probl Dermatol 1993 21 122 153 Boye E Jinnin M Olsen B R Infantile hemangioma: challenges, new insights, and therapeutic promise Journal of Craniofacial Surgery 2009 20 678 84 Bauland Constantijn G. Lüning Thomas H. Smit Jeroen M. Zeebregts Clark J. Spauwen Paul H. M. Untreated Hemangiomas: Growth Pattern and Residual Lesions Plastic and Reconstructive Surgery 2011 127 1643 1648 0032-1052 Ovid Technologies (Wolters Kluwer Health) 10.1097/prs.0b013e318208d2ac https://dx.doi.org/10.1097/prs.0b013e318208d2ac Mao X H W Yan J Y J L Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety Journal of Zhejiang University Science B 2012 13 9 3437372 3437372 Sethuraman Gomathy Yenamandra VamsiK Gupta Vishal Management of infantile hemangiomas: Current trends Journal of Cutaneous and Aesthetic Surgery 2014 7 2 75 75 0974-2077 10.4103/0974-2077.138324 Medknow https://dx.doi.org/10.4103/0974-2077.138324 Blei Francine Walter Jeffrey Orlow Seth J. Marchuk Douglas A. Familial Segregation of Hemangiomas and Vascular Malformations as an Autosomal Dominant Trait Archives of Dermatology 1998 134 6 718 740 0003-987X 10.1001/archderm.134.6.718 American Medical Association (AMA) https://dx.doi.org/10.1001/archderm.134.6.718 Higgins J P Green S Cochrane Handbook for Systematic Reviews of Interventions (Identifying and measuring heterogeneity) 2011 Boon Laurence M. MacDonald Dorothy M. Mulliken John B. Complications of Systemic Corticosteroid Therapy for Problematic Hemangioma Plastic and Reconstructive Surgery 1999 104 1616 1623 0032-1052 Ovid Technologies (Wolters Kluwer Health) 10.1097/00006534-199911000-00002 https://dx.doi.org/10.1097/00006534-199911000-00002 JACOBS ALVIN H. WALTON ROBERT G. THE INCIDENCE OF BIRTHMARKS IN THE NEONATE Obstetrical & Gynecological Survey 1977 32 2 94 95 0029-7828 10.1097/00006254-197702000-00014 Ovid Technologies (Wolters Kluwer Health) https://dx.doi.org/10.1097/00006254-197702000-00014 Frieden I J Which hemangiomas to treat--and how? Arch Dermatol 1997 133 12 9420551 9420551 Schwarzer G General Package for Meta-Analysis. 4.9 7 2019 2019 Alper Joseph C. Holmes Lewis B. The Incidence and Significance of Birthmarks in a Cohort of 4,641 Newborns Pediatric Dermatology 1983 1 1 58 68 0736-8046 10.1111/j.1525-1470.1983.tb01093.x Wiley https://dx.doi.org/10.1111/j.1525-1470.1983.tb01093.x Guo Z L Xu G Gao Q Li Y Zhang P Duan X Guo Y Zheng X B Clinical observations on the treatment of infantile hemangiomas with topical imiquimod 5% cream Journal of Nanjing Medical University 2009 23 3 60051 60055 Munden A. Butschek R. Tom W.L. Marshall J. S. Poeltler D. M. Krohne S.E. Alió A.B. Ritter M. Friedlander D.F. Catanzarite V. Mendoza A. Smith L. Friedlander M. Friedlander S. F. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies British Journal of Dermatology 2014 170 4 907 913 0007-0963 10.1111/bjd.12804 Wiley https://dx.doi.org/10.1111/bjd.12804 Pu ttgen K. Lucky A. Adams D. Pope E. McCuaig C. Powell J. Feigenbaum D. Savva Y. Baselga E. Holland K. Drolet B. Siegel D. Morel K. D. Garzon M. C. Mathes E. Lauren C. Nopper A. Horii K. Newell B. Song W. Frieden I. Topical Timolol Maleate Treatment of Infantile Hemangiomas PEDIATRICS 2016 138 3 e20160355 e20160355 0031-4005, 1098-4275 10.1542/peds.2016-0355 American Academy of Pediatrics (AAP) https://dx.doi.org/10.1542/peds.2016-0355 Chinnadurai S Snyder K Sathe N Fonnesbeck C Morad A Likis F E Diagnosis and Management of Infantile Hemangioma AHRQ Comparative Effectiveness Reviews 2016 Health N I O Quality assessment tool for observational cohort and cross-sectional studies. National Heart, Lung, and Blood Institute Avaliable from: www nhlbi nih gov/health-pro/guidelines/indevelop/cardiovascular-risk-reduction/tools/cohort 2014 Olsen Elise A. Cornell Roger C. Topical clobetasol-17-propionate: Review of its clinical efficacy and safety Journal of the American Academy of Dermatology 1986 15 2 246 255 0190-9622 10.1016/s0190-9622(86)70164-3 Elsevier BV https://dx.doi.org/10.1016/s0190-9622(86)70164-3 Chang James Most Daniel Bresnick Stephen Mehrara Babak Steinbrech Douglas S. Reinisch John Longaker Michael T. Turk Andrew E. Proliferative Hemangiomas: Analysis of Cytokine Gene Expression and Angiogenesis Plastic and Reconstructive Surgery 1999 103 1 9 0032-1052 Ovid Technologies (Wolters Kluwer Health) 10.1097/00006534-199901000-00001 https://dx.doi.org/10.1097/00006534-199901000-00001 Leung Amy Heal Clare Perera Marlon Pretorius Casper A systematic review of patient-related risk factors for catheter-related thrombosis Journal of Thrombosis and Thrombolysis 2015 40 3 363 373 0929-5305, 1573-742X 10.1007/s11239-015-1175-9 Springer Science and Business Media LLC https://dx.doi.org/10.1007/s11239-015-1175-9 Ho Nhung T.C. Lansang Perla Pope Elena Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study Journal of the American Academy of Dermatology 2007 56 1 63 68 0190-9622 10.1016/j.jaad.2006.06.011 Elsevier BV https://dx.doi.org/10.1016/j.jaad.2006.06.011 Hand Jennifer L. Frieden Ilona J. Vascular birthmarks of infancy: Resolving nosologic confusion American Journal of Medical Genetics 2002 108 4 257 264 0148-7299, 1096-8628 10.1002/ajmg.10161 Wiley https://dx.doi.org/10.1002/ajmg.10161 Luu M. Frieden I.J. Haemangioma: clinical course, complications and management British Journal of Dermatology 2013 169 1 20 30 0007-0963 10.1111/bjd.12436 Wiley https://dx.doi.org/10.1111/bjd.12436 Poetke Margitta Philipp Carsten Berlien Hans Peter Flashlamp-Pumped Pulsed Dye Laser for Hemangiomas in Infancy Archives of Dermatology 2000 136 5 628 660 0003-987X 10.1001/archderm.136.5.628 American Medical Association (AMA) https://dx.doi.org/10.1001/archderm.136.5.628 Guo S Ni N Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution Arch Ophthalmol 2010 128 2 255 261 Gilbertson Erik O. Spellman Mary C. Piacquadio Daniel J. Mulford Mim I. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations Journal of the American Academy of Dermatology 1998 38 2 318 321 0190-9622 10.1016/s0190-9622(98)70573-0 Elsevier BV https://dx.doi.org/10.1016/s0190-9622(98)70573-0 Chiller K G Passaro D Frieden I J Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex Arch Dermatol 2002 138 12 1567 76 Kushner Burton J. The Treatment of Periorbital Infantile Hemangioma with Intralesional Corticosteroid Plastic and Reconstructive Surgery 1985 76 517 524 0032-1052 Ovid Technologies (Wolters Kluwer Health) 10.1097/00006534-198510000-00005 https://dx.doi.org/10.1097/00006534-198510000-00005 Egger M. Smith G. D. Schneider M. Minder C. Bias in meta-analysis detected by a simple, graphical test BMJ 1997 315 7109 629 634 0959-8138, 1468-5833 10.1136/bmj.315.7109.629 BMJ https://dx.doi.org/10.1136/bmj.315.7109.629 Peters J L Sutton A J Jones D R Abrams K R Rushton L Comparison of two methods to detect publication bias in meta-analysis Jama 2006 295 6 676 80 Schön M Schön M P The antitumoral mode of action of imiquimod and other imidazoquinolines Curr Med Chem 2007 14 6 681 688 Drolet Beth A. Esterly Nancy B. Frieden Ilona J. Hemangiomas in Children New England Journal of Medicine 1999 341 3 173 181 0028-4793, 1533-4406 10.1056/nejm199907153410307 Massachusetts Medical Society https://dx.doi.org/10.1056/nejm199907153410307 Metry Denise Walker Hebert Adelaide A. Benign Cutaneous Vascular Tumors of Infancy Archives of Dermatology 2000 136 7 905 919 0003-987X 10.1001/archderm.136.7.905 American Medical Association (AMA) https://dx.doi.org/10.1001/archderm.136.7.905 Collins Finn Mary Glowacki Julie Mulliken John B. Congenital vascular lesions: Clinical application of a new classification Journal of Pediatric Surgery 1983 18 6 894 900 0022-3468 10.1016/s0022-3468(83)80043-8 Elsevier BV https://dx.doi.org/10.1016/s0022-3468(83)80043-8 Mccuaig C C D Powell J Belleville J David C Rousseau M Gendron E Jafarian R F Auger, I. A Phase II, Open-Label Study of the Efficacy and Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma Pediatr Dermatol 2009 26 2 203 215 Novoa M Baselga E Beltran S Giraldo L Shahbaz A Pardo-Hernandez H Interventions for infantile haemangiomas of the skin Cochrane Database Syst Rev 2018 4 4 29667726 29667726 Callahan Alison B. Yoon Michael K. Infantile hemangiomas: A review Saudi Journal of Ophthalmology 2012 26 3 283 291 1319-4534 10.1016/j.sjopt.2012.05.004 Elsevier BV https://dx.doi.org/10.1016/j.sjopt.2012.05.004 Vassar Matt Atakpo Paul Kash Melissa J Manual search approaches used by systematic reviewers in dermatology Journal of the Medical Library Association : JMLA 2016 104 4 302 304 1536-5050, 1558-9439 10.3163/1536-5050.104.4.009 University Library System, University of Pittsburgh https://dx.doi.org/10.3163/1536-5050.104.4.009 Jiang C H Ma X Chen G Jin D Chen Y Chen H Lin X X A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma Pediatric Dermatology 2011 28 3 259 66 Haggstrom A. N. Drolet B. A. Baselga E. Chamlin S. L. Garzon M. C. Horii K. A. Lucky A. W. Mancini A. J. Metry D. W. Newell B. Nopper A. J. Frieden I. J. Prospective Study of Infantile Hemangiomas: Clinical Characteristics Predicting Complications and Treatment PEDIATRICS 2006 118 3 882 887 0031-4005, 1098-4275 10.1542/peds.2006-0413 American Academy of Pediatrics (AAP) https://dx.doi.org/10.1542/peds.2006-0413 Liberati Alessandro Altman Douglas G. Tetzlaff Jennifer Mulrow Cynthia Gøtzsche Peter C. Ioannidis John P. A. Clarke Mike Devereaux P. J. Kleijnen Jos Moher David The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration PLoS Medicine 2009 6 7 e1000100 e1000100 1549-1676 10.1371/journal.pmed.1000100 Public Library of Science (PLoS) https://dx.doi.org/10.1371/journal.pmed.1000100 Qiu Y Ma G Lin X Jin Y Chen H Hu X Treating protruding infantile hemangiomas with topical imiquimod 5% cream caused severe local reactions and disfiguring scars Pediatric dermatology 2013 30 3 342 349 McCuaig Catherine C. Dubois Josée Powell Julie Belleville Claude David Michèle Rousseau Élisabeth Gendron Roxanne Jafarian Fatemeh Auger Isabelle A Phase II, Open-Label Study of the Efficacy and Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma Pediatric Dermatology 2009 26 2 203 212 0736-8046, 1525-1470 10.1111/j.1525-1470.2008.00857.x Wiley https://dx.doi.org/10.1111/j.1525-1470.2008.00857.x Haggstrom Anita N. Drolet Beth A. Baselga Eulalia Chamlin Sarah L. Garzon Maria C. Horii Kimberly A. Lucky Anne W. Mancini Anthony J. Metry Denise W. Newell Brandon Nopper Amy J. Frieden Ilona J. Prospective Study of Infantile Hemangiomas: Demographic, Prenatal, and Perinatal Characteristics The Journal of Pediatrics 2007 150 3 291 294 0022-3476 10.1016/j.jpeds.2006.12.003 Elsevier BV https://dx.doi.org/10.1016/j.jpeds.2006.12.003 Seirafi H E Amirhooshang ; Jesri Shabboo ; Gholamali Fatemeh ; Noormohammadpour Pedram Treatment of infantile hemangioma with topical imiquimod 5% cream 2012 Castrén Eeva Salminen Päivi Vikkula Miikka Pitkäranta Anne Klockars Tuomas Inheritance Patterns of Infantile Hemangioma Pediatrics 2016 138 5 e20161623 e20161623 0031-4005, 1098-4275 10.1542/peds.2016-1623 American Academy of Pediatrics (AAP) https://dx.doi.org/10.1542/peds.2016-1623 Qiu Y M Lin G Jin X Chen Y Hu H X Treating protruding infantile hemangiomas with topical imiquimod 5% cream caused severe local reactions and disfiguring scars Pediatric dermatology 2013 30 3 342 349 Enjolras O Mulliken J B Vascular tumors and vascular malformations (new issues) Adv Dermatol 1997 13 9551150 9551150 Kilcline Christine Frieden Ilona J. Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature Pediatric Dermatology 2008 25 2 168 173 0736-8046, 1525-1470 10.1111/j.1525-1470.2008.00626.x Wiley https://dx.doi.org/10.1111/j.1525-1470.2008.00626.x Team R C R: A Language and Environment for Statistical Computing Vienna, Austria 2017